Innovative Medicines Initiative

Innovative Medicines Initiative Joint Technology Initiative

The Innovative Medicines Initiative Joint Technology Initiative (JTI) is a unique Public-Private Partnership (PPP) between the pharmaceutical industry represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Communities represented by the European Commission.

The Innovative Medicines Initiative JTI's overall goal is to make Europe again the world leader in pharmaceutical research for the benefit of the economy and society, by removing research bottlenecks in the current drug development process.

Innovative Medicines Initiative JTI is a high scale pan-European collaboration between the European Community and the bio-pharmaceutical industry.

This public private partnership is currently the largest of its kind.

Similar initiatives, such as the Critical Path Initiative launched by the US Food and Drug Administration (FDA), are also under way outside Europe.

National initiatives undertaken in Europe, such as the Dutch Top Institute Pharma, also supports collaborative research between industrial and academic teams.

The Innovative Medicines Initiative JTI Joint Undertaking Research Agenda is based on the recommendations of the Strategic Research Agenda that was developed by the European Technology Platform on Innovative Medicines through extensive consultation with a large group of stakeholders from academia, SMEs, regulatory agencies and patient organisations.

To find out more contact
Graham M Mobbs
European Operations Manager
Technology Strategy Board
graham.mobbs@tsb.gov.uk